Olga Timoshkina - Henry Schein Chief Fin

HS2 Stock  EUR 66.06  1.76  2.60%   

Insider

Olga Timoshkina is Chief Fin of Henry Schein
Phone631 843 5500
Webhttps://www.henryschein.com

Henry Schein Management Efficiency

The company has return on total asset (ROA) of 0.0642 % which means that it generated a profit of $0.0642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1211 %, meaning that it generated $0.1211 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities.
Henry Schein has accumulated 1.04 B in total debt with debt to equity ratio (D/E) of 41.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Henry Schein has a current ratio of 1.62, which is within standard range for the sector. Debt can assist Henry Schein until it has trouble settling it off, either with new capital or with free cash flow. So, Henry Schein's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Henry Schein sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Henry to invest in growth at high rates of return. When we think about Henry Schein's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Kevin MoranCardinal Health
N/A
Paul GuggenheimPatterson Companies
63
Stephen MasonCardinal Health
51
Jeffrey ZerilloPrestige Consumer Healthcare
62
Ying KeShanghai Pharmaceuticals Holdin
N/A
Steven CollisAmerisourceBergen
62
Tim RoganPatterson Companies
52
Qingming YuSinopharm Group Co
59
Jianyi MaoShanghai Pharmaceuticals Holdin
50
Mary FritzPrestige Consumer Healthcare
N/A
Tao ZhongShanghai Pharmaceuticals Holdin
51
Lazarus KrikorianAmerisourceBergen
58
Yongzhong LiShanghai Pharmaceuticals Holdin
53
Ola SnowCardinal Health
55
James ClearyAmerisourceBergen
60
Wenxun HuoShanghai Pharmaceuticals Holdin
62
Dawei GeShanghai Pharmaceuticals Holdin
56
Jason HollarCardinal Health
50
Silvana BattagliaAmerisourceBergen
56
Jinqi YuShanghai Pharmaceuticals Holdin
N/A
Les KorshPatterson Companies
53
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. The company was founded in 1932 and is headquartered in Melville, New York. HENRY SCHEIN operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 19000 people. Henry Schein (HS2) is traded on Frankfurt Exchange in Germany and employs 22,000 people.

Management Performance

Henry Schein Leadership Team

Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.

Henry Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Henry Stock

When determining whether Henry Schein offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Henry Schein's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Henry Schein Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Henry Schein Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Henry Stock please use our How to Invest in Henry Schein guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.